Arvinas reports preclinical data for PROTAC BCL6 degrader ARV-393 at EHA 2025

ARVINAS, INC.

Single-agent ARV-393 reduced tumor burden in peripheral blood, bone marrow, and spleen in nTFHL-AI PDX model from a post-chemo relapsed patient.
ARV-393 monotherapy achieved ≥95% tumor growth inhibition (TGI) in two PDX models of transformed follicular lymphoma (tFL).
Combinations with 5 small molecule inhibitors (tazemetostat, palbociclib, everolimus, acalabrutinib, venetoclax) enhanced TGI; regressions seen with 4 of 5.
Phase 1 study (NCT06393738) enrolling relapsed/refractory non-Hodgkin lymphoma patients, including DLBCL and AITL.
Data suggest broad utility across NHL subtypes and support chemotherapy-free combination strategies.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.